HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy.

AbstractOBJECTIVE:
Botulinum toxin (BoNT-A) is widely used in combined treatment for spastic cerebral palsy, but its added value preceding comprehensive rehabilitation for motor impairments, gait, and goal attainment has not been studied.
DESIGN:
A comparative multi-centre trial, in which two groups underwent comprehensive rehabilitation (i.e. high-intensive functional physiotherapy, and indicated casting/orthoses). One group received intramuscular BoNT-A prior to rehabilitation, and the other group did not receive BoNT-A.
SUBJECTS/PATIENTS:
Children with spastic cerebral palsy, Gross Motor Function Classification System (GMFCS) levels I-III, age range 4-12 years, indicated for BoNT-A treatment regarding mobility problems.
METHODS:
Sixty-five children participated (37 boys), mean age 7.3 years (standard deviation (SD) 2.3, range 4-12 years), equally distributed across GMFCS levels. Forty-one children received BoNT-A+ comprehensive rehabilitation and 24 received comprehensive rehabilitation only. Functional leg muscle strength, passive range of motion, angle of catch, cerebral palsy-related pain, walking speed, kinematic gait parameters, goal attainment, and proxy-reported general functioning were assessed at baseline, primary end-point (12 weeks) and 24-week follow-up. Statistical analyses were performed with linear mixed models.
RESULTS:
At the primary end-point there were no statistically significant differences in treatment effects between the groups, except for the angle-of-catch of the rectus femoris, which was in favour of comprehensive rehabilitation without BoNT-A (12° difference, 95% confidence interval (95% CI) 2:23, p = 0.025). Results at follow-up were similar.
CONCLUSION:
At the group level, treating with BoNT-A prior to comprehensive rehabilitation did not add to the clinical effectiveness of rehabilitation. Thus, BoNT-A prescription and use should be critically reconsidered in this cerebral palsy age- and GMFCS-subgroup.
AuthorsFabienne Schasfoort, Robert Pangalila, Emiel M Sneekes, Coriene Catsman, Jules Becher, Herwin Horemans, Henk J Stam, Annet J Dallmeijer, Johannes B J Bussmann
JournalJournal of rehabilitation medicine (J Rehabil Med) Vol. 50 Issue 8 Pg. 732-742 (Aug 22 2018) ISSN: 1651-2081 [Electronic] Sweden
PMID30080235 (Publication Type: Journal Article, Multicenter Study)
Chemical References
  • Neuromuscular Agents
  • Botulinum Toxins, Type A
Topics
  • Biomechanical Phenomena (physiology)
  • Botulinum Toxins, Type A (therapeutic use)
  • Cerebral Palsy (rehabilitation)
  • Child
  • Child, Preschool
  • Female
  • Gait (physiology)
  • Humans
  • Injections, Intramuscular (methods)
  • Male
  • Neuromuscular Agents (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: